In patients with DMT2 who did not reach their therapeutic goal or failed to maintain it with metformin as a monotherapy (Hb1Ac <7%), it is suggested to add a sulfonylurea having low risk of hypoglycemia (glimepiride, glicazide) when DPP4 or SGLT2 inhibitors are not available or are contraindicated. Here, SLC5A2 is linked to Hypoglycemia.